Navigation Links
Luminex Corporation First Quarter Earnings Release Scheduled for April 29, 2013
Date:4/8/2013

AUSTIN, Texas, April 8, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the first quarter of 2013 on Monday, April 29, 2013 after the close of trading.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2013 on April 29, 2013, at 5:00 p.m. Eastern time.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the website, go to the About Us section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts. If you use this software, press and hold the CTRL key when you click on the Register button. Please contact your IT group if you are unable to override this feature. Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Luminex Corporate Contact:
Harriss T. Currie
Chief Financial Officer and Vice President, Finance
512-219-8020
hcurrie@luminexcorp.com

Luminex Investor Relations Contact:
Matthew D. Scalo
Sr. Director of Investor Relations
512-219-8020
mscalo@luminexcorp.com


'/>"/>
SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Reports First Quarter 2012 Results
2. Luminex Corporation Announces Agreement to Acquire GenturaDx
3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
4. Luminex Corporation Reports Second Quarter 2012 Results
5. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
6. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
7. Luminex Corporation Recognized as Best Technology Company in Austin
8. Luminex Corporation Hosts 10th Annual Planet xMAP Symposium in Monaco
9. Luminex Corporation To Present At Upcoming Investment Conferences In September
10. Luminex Corporation Reports Third Quarter 2012 Results
11. Luminex Corporation To Present At Leerink Swann Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... A Worldwide Clinical Trials expert will ... Victoria Park Plaza in London , 24-25 ... and future advances for late phase research on Wednesday, 24 ... , associate director of project management at Worldwide, will focus ... regulations and standards in late phase research. ...
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... Feb. 10, 2016 Mast Therapeutics, Inc. ... clinical-stage therapies for sickle cell disease and heart failure, ... of 29,090,910 units at a price to the public ... share of the Company,s common stock and one warrant ... at an exercise price of $0.42 per share. The ...
Breaking Medicine Technology:
(Date:2/11/2016)... Ore. (PRWEB) , ... February 11, 2016 , ... ... Medicaid coverage results in significantly higher rates of several common cancer screenings, especially ... resulting in better outcomes and survival rates. , The study,“What Does Medicaid ...
(Date:2/10/2016)... York, NY (PRWEB) , ... February 10, 2016 , ... ... campaign to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery ... the lives of cocoa farmers and the quality of their product, through activities that ...
(Date:2/10/2016)... PA (PRWEB) , ... February 10, 2016 , ... As ... offer two webinars in February 2016. Each webinar features a dynamic expert and ... to benefit their athletes, patients and facilities. Both events are free to attend, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Emergency rooms ... harder to find. Unfortunately, this can leave patients with dental emergencies at risk of ... is now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... San Diego, will bring together more than 200 of the country’s top healthcare ... the future. , “The true benefit of the Forum is the provider-centric perspective, ...
Breaking Medicine News(10 mins):